With an expanding array of therapeutic options emerging for vitiligo, phototherapy remains a safe and effective option

Delayed diagnoses due to pandemic lockdowns tied to years of life lost

FDA grants accelerated approval for the first T cell therapy for a solid tumor cancer

Exposure-adjusted incidence rates similar at one, two years for adverse events in patients with moderate-to-severe plaque psoriasis

Median time interval after the previous cutaneous squamous cell carcinoma decreases after each subsequent cutaneous squamous cell carcinoma

Significant reductions seen in mean Physician Global Assessment scores and in pain, C-reactive protein, IL-6, leukocytes

Both specialists and generalists were 4 percentage points less accurate for diagnosis of images of dark versus light skin

• sNDA is supported by positive data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials and interim results from the Phase 3...

Newly approved medication lowers the need for amputation of fingers or toes

Disparities seen in access to burn centers, with lower access in the South and West and for those with lower income

More patients receiving apremilast achieved modified static Physician Global Assessment of Genitalia response at week 16

Thirty-eight of 51 survivors had FCRI-SF score above the threshold for clinical fear of cancer recurrence

Greatest increased risk for melanoma-specific mortality seen for patients with SLNB-negative disease

Differences in all-cause, vitiligo-related health care costs remained higher for those on treatments with systemic effects/mental health diagnoses

Percentage of patients with PASI-75 response was higher with the interleukin-23-receptor antagonist peptide

For Immediate Distribution & Release

Canagliflozin significantly more likely to cause pruritus than insulin lispro or insulin glargine

Adjunctive handheld RCM improves diagnostic accuracy of lesions clinically suspicious for basal cell carcinoma

Strong recommendations made for benzoyl peroxide, topical retinoids, topical antibiotics, oral doxycycline

Gender queer and transgender individuals more likely to report discomfort than sexual minority cisgender females, males

Evidence from review supports efficacy of dapsone and sulfasalazine as adjuvant therapies

Between 11 and 59 percent of patients had tuberculosis screening within six months before treatment

Metabolic changes associated with progression-free survival in patients receiving pembrolizumab